Hudson Bay Capital Management LP Glycomimetics Inc Transaction History

Hudson Bay Capital Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 13, 2019	SELL	$2.8 - $12.85 $840,000 - $3.86 Million	-300,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$10.6 - $13.12 $530,000 - $656,000	50,000 Added 20.0%	300,000 $3.58 Million
Q1 2019 May 15, 2019	SELL	$9.96 - $13.44 $996,000 - $1.34 Million	-100,000 Reduced 28.57%	250,000 $3.12 Million
Q4 2018 Feb 13, 2019	BUY	$8.47 - $14.71 $1.52 Million - $2.65 Million	180,000 Added 105.88%	350,000 $3.32 Million
Q3 2018 Nov 14, 2018	BUY	$13.7 - $17.12 $685,000 - $856,000	50,000 Added 41.67%	170,000 $2.45 Million
Q2 2018 Aug 13, 2018	BUY	$14.63 - $19.19 $292,600 - $383,800	20,000 Added 20.0%	120,000 $1.94 Million
Q1 2018 May 14, 2018	SELL	$16.06 - $25.35 $642,400 - $1.01 Million	-40,000 Reduced 28.57%	100,000 $1.62 Million
Q4 2017 Feb 12, 2018	BUY	$10.51 - $17.22 $157,650 - $258,299	15,000 Added 12.0%	140,000 $2.35 Million
Q3 2017 Nov 13, 2017	BUY	$10.14 - $14.85 $1.27 Million - $1.86 Million	125,000	125,000 $1.75 Million

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $13.6M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.